Cara Therapeutics Inc (NAS:CARA)
$ 0.378 -0.0719 (-15.98%) Market Cap: 20.73 Mil Enterprise Value: -13.94 Mil PE Ratio: 0 PB Ratio: 37.80 GF Score: 35/100

Cara Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 04:15PM GMT
Release Date Price: $12.13 (+3.15%)
Daniel G. Wolle
JPMorgan Chase & Co, Research Division - Analyst

Welcome, everyone. We're continuing the 40th JPM conference. I'm one of the associates at the Smid-Cap biotech research team. My name is Daniel Wolle. I'm joined today by President and CEO, Chris Posner of Cara Therapeutics. If you want to ask questions, as a reminder, there is a big blue ask-a-question button you can submit that, and I can ask the questions to the question portal.

Without further ado, Chris?

Christopher A. Posner
Cara Therapeutics, Inc. - President, CEO & Director

Yes. Thank you, Daniel. It's really an exciting time for Cara Therapeutics. It's exciting as we transition to a fast-growing commercial stage company with an approved product in the U.S. and for late to mid-stage programs in the clinic. And I kind of embody that excitement. And for me personally, I was a Board member at Cara for 3 years and became CEO in November. And moving from the board to the CEO role was really an opportunity. I simply could not pass up given the confidence I have in the company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot